Evidence map›Paper›PMID 31390370›Full record

ArticlePLoS medicine2019

Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysis.

James Yarmolinsky, Caroline L Relton, Artitaya Lophatananon, Kenneth Muir, Usha Menon, Aleksandra Gentry-Maharaj, Axel Walther, Jie Zheng, Peter Fasching, Wei Zheng and 8 more

Open access · goldAbstract read
In one paragraph

Article in PLoS medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 7 pooled it
13.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 7 syntheses or guidelines pooled it, 106 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Global epidemiology of epithelial ovarian cancer.Nature reviews. Clinical oncology · 2024
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 10 institutions in 5 countries.

James YarmolinskyMRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom.
Caroline L ReltonMRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom.
Artitaya LophatananonDivision of Population Health, Health Services Research and Primary Care, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.ORCID 0000-0003-0550-4657
Kenneth MuirDivision of Population Health, Health Services Research and Primary Care, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.ORCID 0000-0001-6429-988X
Usha MenonMRC Clinical Trials Unit, Institute for Clinical Trials and Methodology, University College London, London, United Kingdom.ORCID 0000-0003-3708-1732
Aleksandra Gentry-MaharajMRC Clinical Trials Unit, Institute for Clinical Trials and Methodology, University College London, London, United Kingdom.
Axel WaltherBristol Cancer Institute, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom.ORCID 0000-0001-5427-3467
Jie ZhengMRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom.
Peter FaschingDepartment of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Wei ZhengDivision of Epidemiology, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee, United States of America.ORCID 0000-0003-1226-070X
Woo Yin LingFaculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Sue K ParkDepartment of Preventive Medicine, Seoul National University College of Medicine, Seoul, South Korea.ORCID 0000-0001-5002-9707
Byoung-Gie KimDepartment of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Ji-Yeob ChoiDepartment of Preventive Medicine, Seoul National University College of Medicine, Seoul, South Korea.
Boyoung ParkDepartment of Medicine, College of Medicine, Hanyang University, Seoul, South Korea.ORCID 0000-0003-1902-3184
George Davey SmithMRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom.ORCID 0000-0002-1407-8314
Richard M MartinMRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom.ORCID 0000-0002-7992-7719
Sarah J LewisMRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom.
University Hospitals Bristol NHS Foundation Trust · GBUniversity of Bristol · GBManchester Academic Health Science Centre · GBMRC Clinical Trials Unit at UCL · GBSeoul National University · KRHanyang University · KRSamsung Medical Center · KRUniversitätsklinikum Erlangen · DEUniversity of Malaya · MYVanderbilt University Medical Center · US

Funding

Shanghai Womens Health StudyUM1CA182910 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ZHENG, WEI · 2014 to 2018
$5.9M
Cancer Research UK 19169Cancer Research UK C18281/A19169Cancer Research UK C18281/A20988Department of HealthMedical Research Council MC_UU_00011/1Medical Research Council MC_UU_12013/1-9NCI NIH HHS UM1 CA182910
6 · The paper itself

Abstract

backgroundVarious risk factors have been associated with epithelial ovarian cancer risk in observational epidemiological studies. However, the causal nature of the risk factors reported, and thus their suitability as effective intervention targets, is unclear given the susceptibility of conventional observational designs to residual confounding and reverse causation. Mendelian randomization (MR) uses genetic variants as proxies for risk factors to strengthen causal inference in observational studies. We used MR to evaluate the association of 12 previously reported risk factors (reproductive, anthropometric, clinical, lifestyle, and molecular factors) with risk of invasive epithelial ovarian cancer, invasive epithelial ovarian cancer histotypes, and low malignant potential tumours. METHODS AND

findingsGenetic instruments to proxy 12 risk factors were constructed by identifying single nucleotide polymorphisms (SNPs) that were robustly (P < 5 × 10-8) and independently associated with each respective risk factor in previously reported genome-wide association studies. These risk factors included genetic liability to 3 factors (endometriosis, polycystic ovary syndrome, type 2 diabetes) scaled to reflect a 50% higher odds liability to disease. We obtained summary statistics for the association of these SNPs with risk of overall and histotype-specific invasive epithelial ovarian cancer (22,406 cases; 40,941 controls) and low malignant potential tumours (3,103 cases; 40,941 controls) from the Ovarian Cancer Association Consortium (OCAC). The OCAC dataset comprises 63 genotyping project/case-control sets with participants of European ancestry recruited from 14 countries (US, Australia, Belarus, Germany, Belgium, Denmark, Finland, Norway, Canada, Poland, UK, Spain, Netherlands, and Sweden). SNPs were combined into multi-allelic inverse-variance-weighted fixed or random effects models to generate effect estimates and 95% confidence intervals (CIs). Three complementary sensitivity analyses were performed to examine violations of MR assumptions: MR-Egger regression and weighted median and mode estimators. A Bonferroni-corrected P value threshold was used to establish strong evidence (P < 0.0042) and suggestive evidence (0.0042 < P < 0.05) for associations. In MR analyses, there was strong or suggestive evidence that 2 of the 12 risk factors were associated with invasive epithelial ovarian cancer and 8 of the 12 were associated with 1 or more invasive epithelial ovarian cancer histotypes. There was strong evidence that genetic liability to endometriosis was associated with an increased risk of invasive epithelial ovarian cancer (odds ratio [OR] per 50% higher odds liability: 1.10, 95% CI 1.06-1.15; P = 6.94 × 10-7) and suggestive evidence that lifetime smoking exposure was associated with an increased risk of invasive epithelial ovarian cancer (OR per unit increase in smoking score: 1.36, 95% CI 1.04-1.78; P = 0.02). In analyses examining histotypes and low malignant potential tumours, the strongest associations found were between height and clear cell carcinoma (OR per SD increase: 1.36, 95% CI 1.15-1.61; P = 0.0003); age at natural menopause and endometrioid carcinoma (OR per year later onset: 1.09, 95% CI 1.02-1.16; P = 0.007); and genetic liability to polycystic ovary syndrome and endometrioid carcinoma (OR per 50% higher odds liability: 0.89, 95% CI 0.82-0.96; P = 0.002). There was little evidence for an association of genetic liability to type 2 diabetes, parity, or circulating levels of 25-hydroxyvitamin D and sex hormone binding globulin with ovarian cancer or its subtypes. The primary limitations of this analysis include the modest statistical power for analyses of risk factors in relation to some less common ovarian cancer histotypes (low grade serous, mucinous, and clear cell carcinomas), the inability to directly examine the association of some ovarian cancer risk factors that did not have robust genetic variants available to serve as proxies (e.g., oral contraceptive use, hormone replacement therapy), and the assumption of linear relationships between risk factors and ovarian cancer risk.

conclusionsOur comprehensive examination of possible aetiological drivers of ovarian carcinogenesis using germline genetic variants to proxy risk factors supports a role for few of these factors in invasive epithelial ovarian cancer overall and suggests distinct aetiologies across histotypes. The identification of novel risk factors remains an important priority for the prevention of epithelial ovarian cancer.

Indexed as

Age FactorsBody Mass IndexCarcinoma, Ovarian EpithelialFemaleGenetic Predisposition to DiseaseHumansMenarcheMendelian Randomization AnalysisMenopauseOvarian NeoplasmsParityRisk FactorsSmoking

Identifiers

PMID31390370
PMCPMC6685606
OpenAlexW2965579739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.